SPARC Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sun Pharma Advanced Research Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹201.29 |
| 52 Week High | ₹472.80 |
| 52 Week Low | ₹189.75 |
| Beta | 0.88 |
| 1 Month Change | -0.45% |
| 3 Month Change | -5.35% |
| 1 Year Change | -23.94% |
| 3 Year Change | -29.58% |
| 5 Year Change | 28.54% |
| Change since IPO | 130.84% |
Recent News & Updates
Recent updates
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans
Jan 17
Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't
Nov 14Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?
Sep 05Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation
Jun 27Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?
Nov 23If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%
Feb 08
Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?
Dec 14Shareholder Returns
| SPARC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.7% | 1.3% | -3.2% |
| 1Y | -23.9% | 39.0% | 18.7% |
Return vs Industry: SPARC underperformed the Indian Pharmaceuticals industry which returned 39% over the past year.
Return vs Market: SPARC underperformed the Indian Market which returned 18.7% over the past year.
Price Volatility
| SPARC volatility | |
|---|---|
| SPARC Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SPARC has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SPARC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 409 | Anilkumar Raghavan | www.sparc.life |
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures.
Sun Pharma Advanced Research Company Limited Fundamentals Summary
| SPARC fundamental statistics | |
|---|---|
| Market cap | ₹65.32b |
| Earnings (TTM) | -₹4.09b |
| Revenue (TTM) | ₹600.85m |
108.7x
P/S Ratio-16.0x
P/E RatioIs SPARC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPARC income statement (TTM) | |
|---|---|
| Revenue | ₹600.85m |
| Cost of Revenue | ₹376.39m |
| Gross Profit | ₹224.47m |
| Other Expenses | ₹4.31b |
| Earnings | -₹4.09b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.59 |
| Gross Margin | 37.36% |
| Net Profit Margin | -680.16% |
| Debt/Equity Ratio | -114.7% |
How did SPARC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 23:23 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sun Pharma Advanced Research Company Limited is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pankaj Kadu | Axis Capital Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Anubhav Aggarwal | Credit Suisse |